Caring Brands, Inc. Hires Consultant; Appoints Brian R. Meadows to Board

What Happened

• Caring Brands, Inc. announced on Sept. 10, 2026 that it entered a Consulting Services Agreement with Myall Luna Ventures Inc., effective Sept. 2, 2026, for financial and accounting management support coordinated with the Company’s CFO.
• On Sept. 3, 2026 the Board approved, and the appointment became effective Sept. 4, 2026, the addition of Brian R. Meadows to the Board of Directors. The Board determined Mr. Meadows is an independent director under Nasdaq rules.

Key Details

• Consulting Agreement term: Sept. 2, 2026 through Sept. 1, 2027 (no automatic renewal).
• Fee and expenses: $10,000 monthly fee payable in advance; Company will reimburse reasonable, CFO‑approved out‑of‑pocket expenses.
• Termination: Either party may terminate for any reason with at least 30 days’ written notice; fees are earned pro rata and unearned prepaid amounts must be refunded.
• Director appointment: Mr. Brian R. Meadows (President of Myall Luna) became a director on Sept. 4, 2026; his background includes CFO roles at Jones Soda Co. (since 2025), Trubar Inc. and Atmofizer Technologies, plus MBA and CPA/CFA credentials.
• Director compensation: Director Agreement provides an annual grant of options to purchase 25,000 shares under the Company’s Equity Incentive Plan; options expire five years after issuance and have an exercise price equal to market price at issuance.
• The Consulting Agreement is filed as Exhibit 10.1 to the Form 8‑K.

Why It Matters

• The consulting arrangement supplies immediate outsourced finance and accounting support for cash flow management and reporting, which can help the Company meet public‑company reporting and control needs without hiring full‑time staff.
• The appointment of an experienced finance executive to the Board, coupled with equity compensation, aligns governance and oversight with financial expertise; investors should note potential conflicts were considered and the Board deemed Mr. Meadows independent.
• Cost impact is explicit and limited: $10,000/month plus reimbursed expenses and the potential dilution from director option grants (25,000 shares annually).